Trials / Completed
CompletedNCT00630929
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 388 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibuprofen | 800 mg oral tablet 3 times daily with meals for 6 weeks |
| DRUG | Placebo | Matched placebo orally for 6 weeks |
| DRUG | Celecoxib | 200 mg oral capsule once daily with morning meal for 6 weeks |
Timeline
- Start date
- 2003-01-01
- Completion
- 2004-02-01
- First posted
- 2008-03-07
- Last updated
- 2021-02-21
Locations
33 sites across 3 countries: Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00630929. Inclusion in this directory is not an endorsement.